Reaction
Cervix Carcinoma reporting signals
As of the last recalculation, Cervix Carcinoma appears in 3,882 FAERS reports alongside 37 co-occurring drug terms. The strongest observed disproportionality signal is RANITIDINE HYDROCHLORIDE (PRR 22.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ranitidine Hydrochloride | 217 | 22.6 | 22.7 |
| Ranitidine | 652 | 20.9 | 21.0 |
| Fingolimod Hcl | 100 | 6.3 | 6.3 |
| Etonogestrel And Ethinyl Estradiol | 22 | 5.3 | 5.3 |
| Cladribine | 8 | 4.5 | 4.5 |
| Baricitinib | 8 | 4.5 | 4.5 |
| Copper | 34 | 4.3 | 4.3 |
| Peginterferon Beta-1A | 10 | 4.1 | 4.1 |
| Nevirapine | 6 | 3.6 | 3.6 |
| Interferon Beta-1A | 120 | 3.4 | 3.4 |
| Abacavir Sulfate | 6 | 3.3 | 3.3 |
| Infliximab | 129 | 3.2 | 3.2 |
| Conjugated Estrogens And Medroxyprogesterone Acetate | 14 | 3.2 | 3.2 |
| Valsartan And Hydrochlorothiazide | 8 | 3.2 | 3.2 |
| Paclitaxel (Aibumin-Bound) | 47 | 3.1 | 3.1 |
| Ocrelizumab | 35 | 3.0 | 3.0 |
| Raltegravir | 9 | 2.9 | 2.9 |
| Paclitaxel | 53 | 2.9 | 2.9 |
| Methadone | 23 | 2.9 | 2.9 |
| Bevacizumab | 63 | 2.8 | 2.8 |
| Dimethyl Fumarate | 62 | 2.7 | 2.7 |
| Medroxyprogesterone Acetate | 24 | 2.6 | 2.6 |
| Cisplatin | 37 | 2.6 | 2.6 |
| Golimumab | 38 | 2.4 | 2.4 |
| Natalizumab | 79 | 2.4 | 2.4 |
| Upadacitinib | 35 | 2.3 | 2.3 |
| Carboplatin | 51 | 2.2 | 2.2 |
| Risankizumab-Rzaa | 31 | 2.0 | 2.0 |
| Buprenorphine Hydrochloride, Naloxone Hydrochloride | 9 | 2.0 | 2.0 |
| Levonorgestrel | 72 | 1.9 | 1.9 |
| Teriflunomide | 16 | 1.9 | 1.9 |
| Siponimod | 3 | 1.8 | 1.8 |
| Diroximel Fumarate | 4 | 1.8 | 1.8 |
| Ustekinumab | 33 | 1.7 | 1.7 |
| Ofatumumab | 10 | 1.6 | 1.6 |
| Glecaprevir And Pibrentasvir | 3 | 1.5 | 1.5 |
| Glatiramer Acetate | 16 | 1.4 | 1.4 |